Olympus Corp banner

Olympus Corp
TSE:7733

Watchlist Manager
Olympus Corp Logo
Olympus Corp
TSE:7733
Watchlist
Price: 1 555.5 JPY 1.77%
Market Cap: ¥1.7T

EV/S

1.7
Current
35%
Cheaper
vs 3-y average of 2.6

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
1.7
=
Enterprise Value
¥1.5T
/
Revenue
¥987.5B

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
1.7
=
Enterprise Value
¥1.5T
/
Revenue
¥987.5B

Valuation Scenarios

Olympus Corp is trading below its 3-year average

If EV/S returns to its 3-Year Average (2.6), the stock would be worth ¥2 375.3 (53% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-34%
Maximum Upside
+83%
Average Upside
25%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 1.7 ¥1 555.5
0%
3-Year Average 2.6 ¥2 375.3
+53%
5-Year Average 3.1 ¥2 845.66
+83%
Industry Average 1.7 ¥1 560.76
+0%
Country Average 1.1 ¥1 019.12
-34%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
¥1.5T
/
Jan 2026
¥987.5B
=
1.7
Current
¥1.5T
/
Mar 2026
¥1T
=
1.5
Forward
¥1.5T
/
Mar 2027
¥1.1T
=
1.5
Forward
¥1.5T
/
Mar 2028
¥1.1T
=
1.4
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close
Market Cap EV/S P/E
JP
Olympus Corp
TSE:7733
1.7T JPY 1.7 20.2
US
Intuitive Surgical Inc
NASDAQ:ISRG
167.2B USD 16 58.6
US
Abbott Laboratories
NYSE:ABT
161.2B USD 3.6 25.7
US
Stryker Corp
NYSE:SYK
125.8B USD 5.4 38.8
IE
Medtronic PLC
NYSE:MDT
106.4B USD 3.5 23.1
US
Boston Scientific Corp
NYSE:BSX
88.9B USD 4.8 24.9
US
Edwards Lifesciences Corp
NYSE:EW
48.5B USD 7.1 44.2
DE
Siemens Healthineers AG
XETRA:SHL
40.1B EUR 2 18.9
US
IDEXX Laboratories Inc
NASDAQ:IDXX
45.8B USD 10.7 43.3
US
Becton Dickinson and Co
NYSE:BDX
42.8B USD 2.7 24.3
US
Resmed Inc
NYSE:RMD
32.3B USD 5.8 21.8

Market Distribution

In line with most companies in Japan
Percentile
65th
Based on 5 140 companies
65th percentile
1.7
Low
0 — 0.7
Typical Range
0.7 — 2
High
2 —
Distribution Statistics
Japan
Min 0
30th Percentile 0.7
Median 1.1
70th Percentile 2
Max 12 107 466

Olympus Corp
Glance View

Market Cap
1.7T JPY
Industry
Health Care

Olympus Corporation, originating from the heart of Japan in 1919, has evolved into a global powerhouse, particularly revered for its contributions to the field of optics and imaging. Initially carving its reputation through crafting precision microscope lenses, Olympus seamlessly expanded its capabilities into the realms of endoscopy and digital imaging. This strategic pivot not only defined its legacy but firmly anchored its presence in the medical world, where it became a leader in endoscopic technology. The company adeptly leveraged its expertise to revolutionize medical diagnostics and treatment, helping medical professionals see and diagnose better—enhancing both physician dexterity and patient outcomes. Revenue for Olympus is predominantly driven by its Medical Business sector, which constitutes a significant portion of its overall profits, underscoring its transformation from a diversified manufacturer to a specialized player in healthcare technology. They are deeply committed to R&D, funneling substantial resources to innovate and bolster their portfolio in medical devices, particularly in fields like therapeutic interventions. While imaging products for consumers have historically been a notable segment, the shift toward medical technology aligns with broader market demands and ensures sustainable growth. This focus demonstrates Olympus's intent to maximize its competitive advantages, allowing it to remain at the forefront of its niche industries and effectively respond to global healthcare challenges.

Intrinsic Value
2 138.16 JPY
Undervaluation 27%
Intrinsic Value
Price ¥1 555.5
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett